SCHEMBL2716384

SCHEMBL2716384

Cc1cc(C(=O)NCc2ccc(OC(F)(F)F)c(Cl)c2)cc(NC(=O)C(C)C)n1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.53
ROCK2 O75116 1/20 0.48
SCN3A Q9NY46 6/20 0.47
SCN1A P35498 2/20 0.44
SCN5A Q14524 2/20 0.44
SCN2A Q99250 2/20 0.44
SCN8A Q9UQD0 2/20 0.44
SCN10A Q9Y5Y9 2/20 0.44
KCNH2 Q12809 1/20 0.44
KCNB1 Q14721 1/20 0.43
RORC P51449 1/20 0.42
LMNA P02545 1/20 0.41
WDR5 P61964 3/20 0.41
PTGES O14684 2/20 0.41
HSD17B13 Q7Z5P4 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18266802 0.93 SCN9A (0.52) SCN9AROCK2SCN3ASCN1ASCN5A
SCHEMBL2714516 0.92 SCN9A (0.49) SCN9AROCK2KCNB1WDR5
SCHEMBL2713199 0.90 SCN9A (0.48) SCN9AROCK2SCN3AKCNB1
SCHEMBL2714086 0.90 ROCK2 (0.50) SCN9AROCK2SCN3ASCN1ASCN5A
SCHEMBL2715396 0.88 SCN9A (0.48) SCN9AROCK2SCN3AKCNB1PTGES
SCHEMBL2715174 0.86 SCN9A (0.51) SCN9AKCNH2KCNB1LMNAWDR5
SCHEMBL2713838 0.86 SCN9A (0.55) SCN9AROCK2SCN3ASCN1ASCN5A
SCHEMBL2714916 0.86 EPHX2 (0.53) SCN9AKCNB1PTGESGAA
SCHEMBL2715099 0.84 SCN9A (0.56) SCN9AROCK2SCN3A
SCHEMBL2715135 0.83 KCNB1 (0.56) SCN9AROCK2KCNH2KCNB1WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP claimed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US claimed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US claimed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP claimed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO claimed
CN-106478497-B Arylamine derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 CN disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A SCN9A 31/4885ROCK2 4206/4885SCN3A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.